<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Rectal Cancer | Seppälä Lab</title><link>https://www.seppalalab.org/tag/rectal-cancer/</link><atom:link href="https://www.seppalalab.org/tag/rectal-cancer/index.xml" rel="self" type="application/rss+xml"/><description>Rectal Cancer</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en</language><lastBuildDate>Mon, 06 May 2024 00:00:00 +0000</lastBuildDate><image><url>https://www.seppalalab.org/media/logo_hu_e3f0d28ad302f75b.png</url><title>Rectal Cancer</title><link>https://www.seppalalab.org/tag/rectal-cancer/</link></image><item><title>NORPPA-1: A Phase II Trial of Non-Operative Management in Rectal Cancer</title><link>https://www.seppalalab.org/post/2024-norppa1-rectal-cancer/</link><pubDate>Mon, 06 May 2024 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/post/2024-norppa1-rectal-cancer/</guid><description>&lt;p&gt;The NORPPA-1 study (Nordic ORgan Preservation Pilot Approach) is a nonrandomized single-arm clinical trial evaluating non-operative management for rectal cancer, led by Toni Seppälä at Tampere University Hospital (Tays). All 13 surgical units treating rectal cancer in Finland and Estonia are participating.&lt;/p&gt;
&lt;p&gt;Currently, rectal cancer is typically treated with surgery that often impacts patients&amp;rsquo; quality of life permanently, frequently requiring permanent colostomy. The study focuses on patients whose tumour disappears completely after pre-treatment with radiation and chemotherapy. These patients are monitored closely instead of proceeding to surgery — every three months for the first two years, then every six months for three years.&lt;/p&gt;
&lt;p&gt;Around 20% of patients are expected to experience recurrence and will undergo surgery as per current guidelines. For those who avoid surgery entirely, the benefit to quality of life is significant.&lt;/p&gt;
&lt;p&gt;The study also investigates why some tumours respond fully to pre-treatment while others do not, examining tumour composition and the cell types that drive recurrence.&lt;/p&gt;
&lt;p&gt;&lt;a href="https://www.pirha.fi/w/tutkija-toni-seppala-taysista-milloin-perasuolisyopaa-voi-hoitaa-ilman-leikkausta-" target="_blank" rel="noopener"&gt;Read the full article at Pirha.fi →&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href="https://clinicaltrials.gov/study/NCT06328361" target="_blank" rel="noopener"&gt;View trial registration at ClinicalTrials.gov (NCT06328361) →&lt;/a&gt;&lt;/p&gt;</description></item></channel></rss>